Abstract

A method for assisting with appetite and weight control and reduction in obese human patients, which comprises the step of orally or rectally administering an appetite-suppressant compound selected from the group consisting of femoxetine and a pharmaceutically-acceptable salt thereof in an effective appetite-suppressant amount over a period of at least eight (8) weeks is disclosed. The appetite-suppresssant compound is preferably orally administered together with a pharmaceutically-acceptable carrier in a daily dosage of 100 to 1,000 mg in the form of a tablet containing about 100 to 300 mg of the appetite-suppressant compound, which is preferably a pharmaceutically-acceptable femoxetine acid addition salt, especially the hydrochloride.

Other References

• International J. of Obesity 1, pp. 15-42 (1977)--J. E. Blundell
• Central Mechanisms of Ansr.-Drugs, pp. 83-109 (1978)--Garattin et al. or Blundell et al
• Life Sciences 28, 77-82, (1981)--Hoebel et al
• Drugs 10(4), 241--328 (1975)-Pinder et al
• Alimentayinne Metabolism Nutrizione 1, 383 (1980), Wollesen et al
• European J. of Pharm. 32, 108-115 (1975)--Lassen et al
• Psychopharmacologia 42, 21-26 (1975)--Lassen et al
• J. Chromatogr. 133, 147-152 (1977)--Bechgaard et al
• Analytica Chimica Acta, 99, 189-192 (1978)--Bechgaard et al
• J. Neurochemistry 24,47-50 (1975)--Squires
• Lancet 1, 503-505 (1973)--Stunkard et al
• Brit. J. of Psg. 123, 501-507 (1973)--Paykel et al
• J. Pharm. Pharmac. 28, 318-320 (1976)--Goudie et al
• Arzneim-Forsch (Drug Res.) 25 (11), 1758-1762 (1975)--Duhault et al
• European J. of Pharmacol. 40, 121-130 (1976)--Sugrue et al